ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2023, Vol. 32 ›› Issue (1): 95-99.DOI: 10.3969/j.issn.1006-298X.2023.01.020

• • 上一篇    

血液透析患者合并获得性凝血因子V缺乏症

  

  • 出版日期:2023-02-28 发布日期:2023-02-23

Acquired factor V deficiency in a hemodialysis patient

  • Online:2023-02-28 Published:2023-02-23

摘要: 42岁男性患者,规律血液透析1月,因“乏力、气短1 d”就诊。实验室检查显示凝血酶原时间、活化部分凝血活酶时间(APTT)显著延长,APTT纠正试验无法纠正,凝血酶时间正常,凝血因子V活性降低,抑制物检测阳性,予以糖皮质激素单药治疗后凝血功能恢复正常。患者预后良好,在一年的随访中未复发。获得性凝血因子V缺乏症很罕见,临床表现具有异质性,在有基础病患者群中预后不良,及时的诊断和治疗有助于改善患者预后,但需警惕药物相关并发症。


关键词: 尿毒症, 血液透析, 获得性凝血因子V缺乏症, 获得性凝血因子V抑制物, 糖皮质激素

Abstract: A 42yearold male on regular hemodialysis for one month was referred to our hospital because of weakness and shortness of breath for one day. Laboratory tests showed markedly prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT), which failed to be corrected by APTT mixing test, and thrombin time (TT) was normal. Factor V (FV) activity was decreased and the FV inhibitor was detected. Blood coagulation function returned to normal after glucocorticoid therapy. The patient had a good prognosis and was recurrencefree during one year of followup. Acquired factor V deficiency is a rare coagulopathy with a variety of clinical presentations, and has a poor prognosis in patients with chronic disease. Early diagnosis and treatment can improve the prognosis, and clinicians need to be aware of drugassociated complications.


Key words: uremia, hemodialysis, acquired factor V deficiency, acquired factor V inhibitor, glucocorticoid